Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand
Adding SGLT2i to standard treatment reduced HF hospitalization and mortality rates and improved QALYs in T2D-HF patients. Nevertheless, they would not be cost-effective at current prices in Thailand.
Authors
- Tanawan Kongmalai (ORCID: https://orcid.org/0000-0002-1192-9267)
- Phorntida Hadnorntun
- Varalak Srinonprasert (ORCID: https://orcid.org/0000-0001-5311-7657)
- Juthamas Prawjaeng (ORCID: https://orcid.org/0000-0003-3356-7890)
- Pattara Leelahavarong (ORCID: https://orcid.org/0000-0002-9584-0293)
- Usa Chaikledkaew (ORCID: https://orcid.org/0000-0001-9457-9823)
- Ammarin Thakkinstian (ORCID: https://orcid.org/0000-0001-9991-386X)
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
- Ramathibodi Hospital (TH)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-09-22
- DOI
- https://doi.org/10.1007/s41669-024-00526-2
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.15
Funders
- Bill and Melinda Gates Foundation